Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma
Authors:
- 1 September 2014
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 14, S71-S77
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple MyelomaBlood, 2013
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaBlood, 2013
- PomalidomideBlood, 2013
- IMWG consensus on risk stratification in multiple myelomaLeukemia, 2013
- Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyLeukemia, 2013
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulationBritish Journal of Haematology, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple MyelomaJournal of Clinical Oncology, 2004